Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion

The DNA hypomethylating agents decitabine and 5-azacytidine are the only two drugs approved for treatment of all subtypes of the myeloid malignancy myelodysplastic syndromes (MDS). The key to drug activity is incorporation into target cell DNA, however, a practical method to measure this incorporati...

Descripción completa

Detalles Bibliográficos
Autores principales: Chilakala, Sujatha, Feng, Ye, Li, Lan, Mahfouz, Reda, Quteba, Ebrahem, Saunthararajah, Yogen, Xu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418203/
https://www.ncbi.nlm.nih.gov/pubmed/30872721
http://dx.doi.org/10.1038/s41598-019-41070-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418203/
https://www.ncbi.nlm.nih.gov/pubmed/30872721
http://dx.doi.org/10.1038/s41598-019-41070-y

Ejemplares similares